Home / Health / Long COVID Drug Shows Promise in Phase 2 Trial
Long COVID Drug Shows Promise in Phase 2 Trial
26 Oct
Summary
- Investigational drug bezisterim showed improved outcomes in Long COVID patients.
- The drug appeared most effective for those with severe fatigue and cognitive issues.
- Bezisterim demonstrated similar safety and tolerability to placebo.
BioVie Inc. announced promising results from its Phase 2 ADDRESS-LC trial for bezisterim, an investigational therapy for Long COVID. The company was invited to present these findings at a US government-backed workshop focused on accelerating treatments for the condition.
Dr. Penelope Markham will discuss the trial results, which indicated a consistent improvement trend with bezisterim compared to placebo across multiple patient-reported and objective measures. Patients with more severe baseline symptoms, particularly fatigue and cognitive impairment, appeared to benefit the most.
The ADDRESS-LC study, a randomized, placebo-controlled trial, enrolled approximately 200 adults with Long COVID. Bezisterim demonstrated safety and tolerability profiles similar to placebo. These findings are expected to inform the design of a confirmatory Phase 3 trial.
The RECOVER-TLC Initiative, hosted by the National Institute of Allergy and Infectious Diseases and the Foundation for the National Institutes of Health, aims to advance Long COVID treatments. Bezisterim is an oral drug designed to reduce inflammation and improve insulin sensitivity without immune suppression.
